Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations

Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Unilateral Total Knee Replacement - a Randomized, Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02648958

Enrollment

Registered

2016-01-07

Start date

2016-01-31

Completion date

2017-07-31

Last updated

2018-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement

Brief summary

Ischemia reperfusion injury causes the release of free oxygen radicals. The selective alpha2-receptor agonist, dexmedetomidine, has an inhibitory effect on inflammatory responses during ischemic injury. The aim of this study is to evaluate the effect of dexmedetomidine on inflammatory responses during ischemia-reperfusion injury in skeletal muscle.

Interventions

DRUGDexmedetomidine

The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.

DRUGnormal saline

The control group received the normal saline infusion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* American Society Anesthesiologists classification I-III

Exclusion criteria

* use of antioxidants clinically significant cardiovascular, renal, or hepatic diseases heart block greater than the first degree

Design outcomes

Primary

Measure	Time frame
changes of malondialdehyde (μmol/L)	up to 1 day

Secondary

Measure	Time frame
changes of interleukin-6 (pg/ml)	up to 1 day

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026